STANDARDIZATION OF ASSAY FOR ANTIBODIES TO ISLET CELLS

Information

  • Research Project
  • 3495618
  • ApplicationId
    3495618
  • Core Project Number
    R43DK038246
  • Full Project Number
    1R43DK038246-01
  • Serial Number
    38246
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1986 - 38 years ago
  • Project End Date
    6/30/1987 - 37 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1986 - 38 years ago
  • Budget End Date
    6/30/1987 - 37 years ago
  • Fiscal Year
    1986
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -
Organizations

STANDARDIZATION OF ASSAY FOR ANTIBODIES TO ISLET CELLS

The test for islet cell cytoplasmic antibodies (ICA) is a good predictor of individuals at risk to develop Type I diabetes, and thus has potential value in identifying candidates for future measures aimed at preventing the disease. However, problems with standardization limit the reliability of the ICA assay. The goal of this project is to make available a standardized, and hence more reliable system for detecting ICA. Specific objectives are to: 1) establish a protocol for procuring donor pancreas that results in optimal reactivity and retention of tissue morphology; 2) establish the most sensitive and reproducible fluorescent indicator system for visualizing the ICA reaction; 3) maximize the stability of islet cell antigens in tissue sections; and 4) develop a separate parallel system that allows the user to assess his skills in performing, reading and interpreting the ICA test. These aims will be addressed by: 1) documenting time limits for tissue processing beyond which reactivity and histology deteriorate and examining pancreas perfusion as a means of extending these time limits; 2) comparing five fluorescent indicators for specificity, sensitivity and reproducibility in the ICA assay; 3) comparing shelf-lives of pancreas sections after various modes of fixation; and 4) developing the components of a user standardization kit. This research will lay the groundwork for Phase II development of a commercially marketable ICA assay package.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    IMMCO DIAGNOSTICS
  • Organization Department
  • Organization DUNS
  • Organization City
    BUFFALO
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    14228
  • Organization District
    UNITED STATES